CRF Health has been recognized as a leading HealthTech Innovator in the 2017 Global Digital Health 100 Awards. CRF Health was selected as one of the year’s most disruptive technology companies for its innovative TrialMax and TrialConsent solutions, the industry’s first eCOA-native electronic informed consent technology.
Launched in May 2016, TrialConsent is the first hybrid solution to offer eConsent technology and eCOA on a single platform, reducing the need for layering yet another technology in a clinical trial, significantly reducing the burden and complexity for study teams.
“Patient-centered innovation is at the heart of our company, and to be named as a disruptive force in the 2017 Global Digital Health 100 Awards is recognition of our team’s relentless hard work and dedication,” CRF Health’s CEO, Rachael Wyllie said. “Clinical trials are constantly adopting new digital technologies and the line between clinical trials and digital health is no longer clearly discernable. To keep ahead in such a rapidly changing industry – and with enhancing operational efficiency and minimizing costs more important than ever - stakeholders are being driven to implement an array of innovative strategies to retain a viable lead. Clinical trial providers worldwide are progressively relying on data analytics to keep pace. CRF Health’s continuing mission is to manage and deliver actionable patient data with the ultimate aim of helping Life Science sponsors bring new medicines to market safely, quickly and cost-effectively.”